Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Clinical Rheumatology, (2022), 10.1007/s10067-022-06218-8)

Laura C. Coates; Philip Mease; Andris Kronbergs; Cameron Helt; David Sandoval; So Young Park; Bernard Combe; Peter Nash; Atul Deodhar

doi:10.1007/s10067-022-06271-3

Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Clinical Rheumatology, (2022), 10.1007/s10067-022-06218-8)

Laura C. Coates, Philip Mease, Andris Kronbergs, Cameron Helt, David Sandoval, So Young Park, Bernard Combe, Peter Nash, Atul Deodhar

Arthritis and Rheumatic Diseases

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The article “Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results,” written by Laura C. Coates, Philip Mease, Andris Kronbergs, Cameron Helt, David Sandoval, So Young Park, Bernard Combe, Peter Nash, and Atul Deodhar, was originally published electronically on the publisher’s internet portal on 16 May 2019 without open access.

Original language	English (US)
Journal	Clinical Rheumatology
DOIs	https://doi.org/10.1007/s10067-022-06271-3
State	Published - Oct 2022

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1007/s10067-022-06271-3

Fingerprint

Dive into the research topics of 'Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Clinical Rheumatology, (2022), 10.1007/s10067-022-06218-8)'. Together they form a unique fingerprint.

Cite this

Coates, L. C., Mease, P., Kronbergs, A., Helt, C., Sandoval, D., Park, S. Y., Combe, B., Nash, P., & Deodhar, A. (2022). Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Clinical Rheumatology, (2022), 10.1007/s10067-022-06218-8). Clinical Rheumatology. https://doi.org/10.1007/s10067-022-06271-3

Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Clinical Rheumatology, (2022), 10.1007/s10067-022-06218-8). / Coates, Laura C.; Mease, Philip; Kronbergs, Andris et al.
In: Clinical Rheumatology, 10.2022.

Research output: Contribution to journal › Comment/debate › peer-review

Coates, LC, Mease, P, Kronbergs, A, Helt, C, Sandoval, D, Park, SY, Combe, B, Nash, P & Deodhar, A 2022, 'Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Clinical Rheumatology, (2022), 10.1007/s10067-022-06218-8)', Clinical Rheumatology. https://doi.org/10.1007/s10067-022-06271-3

Coates LC, Mease P, Kronbergs A, Helt C, Sandoval D, Park SY et al. Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Clinical Rheumatology, (2022), 10.1007/s10067-022-06218-8). Clinical Rheumatology. 2022 Oct. doi: 10.1007/s10067-022-06271-3

@article{41e8489b8122470196b82f5115c9f32c,

title = "Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Clinical Rheumatology, (2022), 10.1007/s10067-022-06218-8)",

abstract = "The article “Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results,” written by Laura C. Coates, Philip Mease, Andris Kronbergs, Cameron Helt, David Sandoval, So Young Park, Bernard Combe, Peter Nash, and Atul Deodhar, was originally published electronically on the publisher{\textquoteright}s internet portal on 16 May 2019 without open access.",

author = "Coates, {Laura C.} and Philip Mease and Andris Kronbergs and Cameron Helt and David Sandoval and Park, {So Young} and Bernard Combe and Peter Nash and Atul Deodhar",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = oct,

doi = "10.1007/s10067-022-06271-3",

language = "English (US)",

journal = "Clinical Rheumatology",

issn = "0770-3198",

publisher = "Springer London",

}

TY - JOUR

T1 - Correction to

T2 - Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Clinical Rheumatology, (2022), 10.1007/s10067-022-06218-8)

AU - Coates, Laura C.

AU - Mease, Philip

AU - Kronbergs, Andris

AU - Helt, Cameron

AU - Sandoval, David

AU - Park, So Young

AU - Combe, Bernard

AU - Nash, Peter

AU - Deodhar, Atul

PY - 2022/10

Y1 - 2022/10

N2 - The article “Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results,” written by Laura C. Coates, Philip Mease, Andris Kronbergs, Cameron Helt, David Sandoval, So Young Park, Bernard Combe, Peter Nash, and Atul Deodhar, was originally published electronically on the publisher’s internet portal on 16 May 2019 without open access.

AB - The article “Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results,” written by Laura C. Coates, Philip Mease, Andris Kronbergs, Cameron Helt, David Sandoval, So Young Park, Bernard Combe, Peter Nash, and Atul Deodhar, was originally published electronically on the publisher’s internet portal on 16 May 2019 without open access.

UR - http://www.scopus.com/inward/record.url?scp=85134296962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134296962&partnerID=8YFLogxK

U2 - 10.1007/s10067-022-06271-3

DO - 10.1007/s10067-022-06271-3

M3 - Comment/debate

C2 - 35821169

AN - SCOPUS:85134296962

SN - 0770-3198

JO - Clinical Rheumatology

JF - Clinical Rheumatology

ER -

Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Clinical Rheumatology, (2022), 10.1007/s10067-022-06218-8)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this